Clinical Trial Update: Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients [Phase 3]

View source ↗

Summary

A Phase 3 open-label trial of tacrolimus (FK506) in patients with refractory ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tacrolimus (FK506) (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED